Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer
- PMID: 18829480
- PMCID: PMC5108626
- DOI: 10.1158/1078-0432.CCR-08-0167
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer
Abstract
Purpose: To identify the patterns of protein expression of basic fibroblast growth factor (bFGF) and FGF receptors 1 and 2 in non-small cell lung carcinoma (NSCLC) and their role in the early pathogenesis of squamous cell carcinoma (SCC) of the lung.
Experimental design: Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
Results: High expression of bFGF, FGFR1, and FGFR2 was shown in most NSCLC tumors. The pattern of expression for all markers varied according to tumor histologic type and cellular localization. Cytoplasmic expression scores were significantly higher in tumors than in normal epithelia. Nuclear bFGF (P = 0.03) and FGFR1 (P = 0.02) levels were significantly higher in women than in men. Although cytoplasmic FGFR1 expression was significantly higher (P = 0.002) in ever smokers than in never smokers, nuclear FGFR1 (P = 0.0001) and FGFR2 (P = 0.003) expression was significantly higher in never smokers. Different prognostic patterns for the expression of these markers were detected for both NSCLC histologic types. Dysplastic changes showed significantly higher expression of all markers compared with squamous metaplasia.
Conclusions: bFGF, FGFR1, and FGFR2 are frequently overexpressed in SCC and adenocarcinoma of the lung. bFGF signaling pathway activation may be an early phenomenon in the pathogenesis of SCC and thus an attractive novel target for lung cancer chemopreventive and therapeutic strategies.
Figures
Similar articles
-
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.Int J Clin Exp Pathol. 2015 Sep 1;8(9):9760-71. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617686 Free PMC article.
-
Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.Ann Surg Oncol. 2014 May;21(5):1561-8. doi: 10.1245/s10434-013-3456-x. Epub 2014 Jan 3. Ann Surg Oncol. 2014. PMID: 24385208
-
FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21. Clin Cancer Res. 2014. PMID: 24850843
-
Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer.Chin Med J (Engl). 2016 Dec 5;129(23):2868-2872. doi: 10.4103/0366-6999.194649. Chin Med J (Engl). 2016. PMID: 27901003 Free PMC article. Review.
-
Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.Crit Rev Oncol Hematol. 2012 Nov;84(2):149-60. doi: 10.1016/j.critrevonc.2012.02.012. Epub 2012 Apr 9. Crit Rev Oncol Hematol. 2012. PMID: 22494932 Review.
Cited by
-
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.J Clin Invest. 2012 Dec;122(12):4388-400. doi: 10.1172/JCI64048. Epub 2012 Nov 12. J Clin Invest. 2012. PMID: 23143308 Free PMC article.
-
Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.Ann Transl Med. 2018 Apr;6(8):142. doi: 10.21037/atm.2018.04.28. Ann Transl Med. 2018. PMID: 29862231 Free PMC article. Review.
-
High Expression of FGFR4 Enhances Tumor Growth and Metastasis in Nasopharyngeal Carcinoma.J Cancer. 2015 Oct 20;6(12):1245-54. doi: 10.7150/jca.12825. eCollection 2015. J Cancer. 2015. PMID: 26535066 Free PMC article.
-
Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer.Cancers (Basel). 2021 Apr 22;13(9):2023. doi: 10.3390/cancers13092023. Cancers (Basel). 2021. PMID: 33922215 Free PMC article. Review.
-
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.PLoS One. 2010 Feb 9;5(2):e9112. doi: 10.1371/journal.pone.0009112. PLoS One. 2010. PMID: 20161759 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30. - PubMed
-
- Minna JD, Gazdar A. Focus on lung cancer. Cancer Cell. 2002;1:49–52. - PubMed
-
- Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer (IARC); 2004. pp. 9–124.
-
- Wistuba I. Genetics of preneoplasia: Lessons from lung cancer. Curr Mol Med. 2007;7:3–14. - PubMed
-
- Gazdar AF, Minna JD. Angiogenesis and the multistage development of lung cancers. Clin Cancer Res. 2000;6:1611–2. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous